SMO and basal cell carcinoma: SMO antagonists, a class of Hh pathway inhibitors that have been approved by the FDA for treatment of cancers that arise from aberrant Hh signalling as a result of alternations in SMO or elements upstream of SMO (ie basal cell carcinoma and acute myeloid leukaemia) have been reported to have teratogenic effects and foetal toxicity.25